Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD4+ T cell receptor complex recognizing Hepatitis C Virus (HCV) peptide–MHC class II is a critical mediator of the adaptive immune response against HCV infection (Source: PMID 15141013). This complex consists of the T-cell receptor (TCR) alpha and beta chains, the CD3 signaling subunits, and the CD4 co-receptor, which collectively recognize specific HCV-derived peptides presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (Source: UniProt P01730, P07766). Activation of this complex is essential for the recruitment and help of other immune cells, such as B cells for antibody production and CD8+ T cells for viral clearance. In chronic HCV infection, this interaction is often impaired due to T-cell exhaustion or viral escape mutations in the targeted epitopes (Source: PMID 25831558). Therapeutic strategies targeting this complex include the development of peptide-based vaccines, such as IC41, designed to boost specific CD4+ T-cell responses, and the engineering of TCR-transduced T cells for adoptive immunotherapy (Source: PMID 18671478). Understanding the structural and functional nuances of this complex is vital for designing interventions that can overcome viral persistence and promote spontaneous or treatment-induced clearance of the virus.
The complex recognizes specific HCV peptides presented by MHC class II molecules, triggering signaling through the CD3 complex to activate CD4+ helper T cells, which coordinate the antiviral immune response (Source: PMID 11752708).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4+ T cell receptor complex recognizing Hepatitis C Virus peptide–MHC class II (CD4+ TCR-HCV-pMHCII).